PCSK9 Inhibitors
<p>Dec 23, 2012 08:47 PM</p>
<p>note: SIX companies working on this!!! Amgen, Merck, Aventis, Isis, Santaris and Alnylam Pharm. !!!!</p>
<p>companies beginning phase III trials...</p>
<p>major role in CHOLES homeostasis...</p>
<p>binds to EGF repeat of LDLR = ldl receptor which INDUCES LDLR DEGRADATION!!!!!</p>
<p>reduced LDLR => decr metab of LDL => incr Cholestterol!</p>
<p><strong>LDL cholesterol is removed from the blood when it binds to LDL receptors on the surface of liver cells</strong>, and is taken inside the cells.<strong> When PCSK9 binds to the LDL receptor, the receptor is destroyed along with the LDL.</strong>
But if PCSK9 does not bind, the receptor can return to the surface of the cell and remove more cholesterol...</p>
<p>Dec 23,...</p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>